SCHEMBL25679573

SCHEMBL25679573

C=C1c2cccc(NC(C)C)c2CN1C1CCC(=O)NC1=O

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 16/20 0.61
DDB1 Q16531 7/20 0.61
IKZF3 Q9UKT9 5/20 0.52
IKZF1 Q13422 2/20 0.52
BRD4 O60885 1/20 0.52
TNF P01375 1/20 0.52
IL1B P01584 1/20 0.52
MAP1LC3B Q9GZQ8 2/20 0.48
CSNK1A1 P48729 1/20 0.45
ALDH1A1 P00352 1/20 0.44
CHRM2 P08172 1/20 0.44
OPRM1 P35372 1/20 0.44
CYP1A2 P05177 1/20 0.44
TSHR P16473 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
IKZF2 Q9UKS7 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19504240 0.91 CRBN (0.53) CRBNDDB1IKZF3IKZF1BRD4
SCHEMBL21304408 0.90 CRBN (0.66) CRBNDDB1IKZF3IKZF1BRD4
SCHEMBL18666833 0.90 CRBN (0.66) CRBNDDB1IKZF3IKZF1BRD4
SCHEMBL25477254 0.84 CRBN (0.52) CRBNDDB1IKZF3IKZF1BRD4
SCHEMBL20992933 0.82 CRBN (0.64) CRBNDDB1IKZF3IKZF1BRD4
SCHEMBL20652915 0.81 CRBN (0.41) CRBNDDB1IKZF3IKZF1BRD4
SCHEMBL25034866 0.80 CRBN (0.53) CRBNDDB1IKZF3IKZF1BRD4
SCHEMBL25766116 0.80 CRBN (0.61) CRBNDDB1IKZF3IKZF1BRD4
SCHEMBL25036779 0.79 CRBN (0.80) CRBNDDB1IKZF3IKZF1BRD4
SCHEMBL25034710 0.79 CRBN (0.63) CRBNDDB1IKZF3IKZF1BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230181746-A1 BENZOYLHYDRAZIDE-DERIVED HDAC DEGRADERS AS THERAPEUTICS FOR TREATING CANCER AND OTHER HUMAN DISEASES UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. 2023-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230181746-A1 BENZOYLHYDRAZIDE-DERIVED HDAC DEGRADERS AS THERAPEUTICS FOR TREATING CANCER AND OTHER HUMAN DISEASES HDAC3, HDAC1, HDAC5 CRBN 208/4885DDB1 683/4885IKZF3 212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.